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 Acute myeloid leukemia (AML) is a cancer with a harsh treatment regimen, affecting 
primarily the elderly.  The partial tandem duplication mutation of the mixed lineage leukemia 
gene (MLL-PTD) is seen in 5-10% of patients with AML and is associated with a poor prognosis 
and a high chance of relapse.  Molecular studies demonstrate that MLL-wild type (WT) 
transcripts are not expressed in MLL-PTD+ AML patient blasts.  It is thus important to study 
how the PTD mutation functions in the absence of MLL-WT.  We first generated a mouse model 
that carries the Mll-PTD mutation on one allele while the second Mll gene remained normal 
[wildtype (WT)]. The generation of the homozygous Mll-PTD animals and also hemizygous Mll-
PTD mice (lacking the Mll-WT gene) was lethal in both cases. This demonstrated that the Mll-
WT is required for full development. Thus, to obtain a scenario that would mimic that observed 
in humans with MLL-PTD (absence of MLL-WT expression), we developed a new mouse model 
that allows for the removal (knockout) of Mll-WT while retaining the Mll-PTD after the newborn 
heterozygous pups obtained adulthood (conditional knockout approach).  Mll-PTD heterozygous 
mice were crossed to Mll-conditional knockout animals to generate MllPTD/F animals also 
expressing Mx1-driven Cre recombinase.  Following induction of Cre recombinase with poly I:C, 
exons 3 and 4 of the floxed Mll (Mll-F) are removed, creating Mll-ΔN, which lacks the 
subnuclear localization domain needed for normal nuclear function.  The resulting PTD/ΔN 
animals thus maintain Mll-PTD as the only nuclear functional copy of Mll in hematopoietic cells.  
PCR analysis of bone marrow and spleen from animals with conditionally induced Cre 
expression demonstrated complete deletion of the Mll-F allele. MllPTD/∆N animals survived past 
500 days (p<0.001) with no signs of bone marrow failure, while Mll∆N/∆N animals died of bone 
marrow failure 18 days after induction on average.  Histopathological analysis of BM samples 
revealed marked hypocellularity in MllΔN/ΔN animals, but no signs of hypocellularity in MllPTD/ΔN 
animals or age-matched normal WT controls. MllPTD/ΔN animals demonstrated no differences in 
white blood cell count (p=0.1693) or hematocrit (p=0.0916) upon sacrifice compared to non-
moribund controls. Preliminary qRT-PCR analysis of BM and spleen samples at 12 days post-
induction revealed a similar 4-5 fold increase of the Mll transcriptional target HoxA9 in MllPTD/ΔN 
and MllPTD/F animals relative to MllF/F animals, consistent with the hypothesis that Mll-PTD acts 
in a gain-of-function manner even in the absence of Mll-WT. MllPTD/ΔN mice show no signs of 
developing acute leukemia suggesting the absence of the WT allele in pts with MLL-PTD AML, 
may be a consequence rather than a cause of leukemic transformation. However, further analysis 
of this unique mouse model provides evidence that the Mll-PTD mutation is capable of 
sustaining normal levels of hematopoiesis in the absence of any Mll-WT expression.  With a 
further understanding of the biology of Mll-PTD positive AML, Mll-PTD itself or its 
downstream targets can be targeted to improve the prognosis of those afflicted with this disease. 
 
Introduction: 
Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) is a cancer of myeloid cells, which are any blood cells 
that are not lymphocytes.  In AML, rapid proliferation of myeloid progenitors known as 
myeloblasts, and a decrease in ability to differentiate and undergo erythropoiesis, 
thrombopoeisis, or leukopoiesis leads to accumulation of immature cells in the bone marrow and 
blood.  AML is primarily a disease of the elderly, with a median age in the United States of 68 
years, and incidence increases nearly tenfold for people over the age of 65.2 Older patients have a 
poorer prognosis than younger patients due to differences in the pathology and basis of the 
disease, as well as their ability to tolerate the current treatments of AML.  Current treatment 
regimens for AML include cytotoxic chemotherapy, bone marrow transplantation, or a 
combination of the two.  Chemotherapy regimens often use an intense treatment of drugs such as 
cytarabine, daunorubicin, or idarubicin, among others, and serve to eliminate the cancerous 
elements of the bone marrow, collaterally destroying healthy cells as well in order to allow for 
the marrow to repopulate with non-cancerous cells.1 Given the harsh side effects of the 
chemotherapy and the intense course of treatment, elderly patients have more difficulty coping 
with the regimen. In addition to chemotherapy, bone marrow transplant may be required to 
encourage remission of the disease.  The allogeneic stem cell transplantation is associated with 
procedural risk, particularly in elderly patients, as well as a risk of developing long-term 
complications such as chronic graft-versus-host disease (GVHD), which can prove to be fatal.1  
Given the severity of current treatments of AML and the poor prognosis for elderly patients, 
therapy for AML patients over the age of 65 often  is solely palliative. 
 
The Mixed-Lineage Leukemia Gene 
 The future of AML treatment must allow for a greater quality of life and prognosis than 
the current treatments used.  Along with age, the other key prognostic factor in AML is 
chromosomal condition.1  Many positive and negative genetic prognostic factors have been 
discovered in AML.  The future of AML treatment lies in novel, personalized therapies specific 
to target each patient’s unique genetic profile in the pathology of their disease.  One gene often 
implicated in AML is the mixed-lineage leukemia (MLL) gene.  Also known as HRX or ALL1, 
MLL encodes for a histone methyltransferase and lies within the breakpoint cluster region in the 
11q23 chromosomal location and is involved in numerous translocations found in human 
leukemias.3  Dr. Patricia Ernst’s analysis of WT MLL have shown multiple regions similar to the 
Trithorax gene in Drosophila melanogaster.4 MLL positively regulates Hox genes, and loss-of-
function analyses of MLL have shown Hoxa4, a5, a7, a9, a10, c4, c5, c6, c94, and Meis1A5 to be 
direct downstream targets of MLL.  Hoxa9 and Hoxa10 are significant players in hematopoietic 
processes as well as embryonic patterning.  Hoxa9 has also been shown to be overexpressed in 
both human and murine AML6, further emphasizing the importance of the MLL gene in AML 
leukemogenesis.  Analysis of yolk sac and fetal liver by Yagi et al. after knocking out Mll 
showed a drastic reduction in hematopoietic cells, further implicating the importance of Mll in 
hematopoiesis.14  MLL fusion mutations involve the translocation of the MLL gene with regions 
of other chromosomes.  MLL fusion mutations have been shown to be sufficient to cause 
leukemia in a mouse model by both Lavau et al. using a myelomonocytic cell line and Corral et 
al. using an Mll-AF9 knock-in model of leukemogenesis.7,8  In leukemias associated with a 
mutation of MLL, treatments that serve to correct the effects of the patient’s specific mutation or 
gene therapy to correct the mutation itself could prove to be effective and less strenuous than the 
current chemotherapeutic regimens. 
 
The Partial Tandem Duplication of MLL 
 In 1994, Caligiuri et al. used an MLL probe to study rearrangements in MLL in adults 
with de novo AML that do not have cytogenetically detectable translocations.  It was found that 
cytogenetically undetectable rearrangements are associated with a poor prognosis.9  The partial 
tandem duplication (PTD) of MLL is  an in-frame duplication that does not create a truncated 
protein. MLL-PTD is a unique mutation as it maintains all functional domains.  In our model, 
exons 5-11 are duplicated and inserted into intron 4.  Exons 5-11 code for the the AT hooks, a 
DNA-binding motif, and the methylbinding domain (Figure 1).10 MLL-PTD was found by 
Schichman and Caligiuri to be present in approximately 5-10% of patients with AML, and is 
associated with a particularly poor prognosis.9  Caligiuri et al. later characterized the mutation in 
AML with trisomy 11, again emphasizing the significance of MLL-PTD in human AML.  Golub 
et al. determined that  HOXA9, a target of MLL, was the gene whose expression correlates most 
with poor prognosis in human AML.17  AML blasts with MLL fusions such as MLL-AF9 express 
the wild-type and fusion transcripts, and MLL fusions require the presence of the MLL wild-type 
gene to function.21 Unlike MLL-AF9 fusions, Whitman et al. found that in MLL-PTD+ AML 
blasts, although the MLL-WT DNA is not lost, the MLL-WT transcript is for the most part absent, 
unlike the MLL-AF9 blasts.12 These data suggested that the wild-type expression is repressed in 
patients with the MLL PTD, and this repression may result from DNA methylation of the MLL 
WT allele. Although the specific mechanisms by which MLL-PTD silences the MLL WT, and 
whether this has a causative role in leukemogenesis, are unknown,11 the MLL PTD is a 
significant prognostic factor and therefore it is important to uncover the mechanisms that 
contribute to the biology of  the leukemic cell to determine how to more effectively treat patients 
harboring the MLL-PTD mutation. 
 
  
A Mouse Model of MLL-PTD 
 Our lab developed and studied a novel mouse model which expresses Mll-PTD under the 
control of the endogenous Mll promoter.  The MllPTD/PTD genotype proved to be embryonic lethal.  
Phenotypic analysis of the MllPTD/WT mouse showed a high penetrance of axial skeletal defects, 
likely due to the elevated transcript levels of Hoxa9, as well as Hoxa7 and Hoxa10 as determined 
by Dorrance et al.13  Despite elevated transcript levels of these downstream Mll targets, MllPTD/WT 
mice do not develop leukemia. 
 As aforementioned, Whitman et al. showed epigenetic silencing of MLL-WT in MLL-
PTD+ AML patient blasts.12 In order to discover the hematopoietic and leukemogenic 
mechanisms of the PTD mutation, it is thus important to look at how the PTD mutation functions 
(or doesn’t function) in the absence of the Mll wild-type gene.  Dorrance et al. crossed our lab’s 
MllPTD/WT  mice with MllWT/- mice obtained from the late Dr. Stanley Korsmeyer to obtain MllPTD/- 
mice in order to study PTD alone, without Mll-WT.  All F1 generation MllPTD/- mice die by 
postpartum day 1.11 Additionally, as Hanson et al. noted, Mll-/- mice are also nonviable, but die 
on average at embryonic day 10.5, as a result of lethal developmental abnormalities and 
abnormal apoptosis, further implicating the role of Mll in cell proliferation and development.  
The comparison of these results and the viability of MllPTD/- embryos versus Mll-/- embryos shows 
that in absence of Mll-WT, Mll-PTD is able to partially compensate for embryonic development, 
even though it is still not enough to allow for sustained viability in these mice.6 These findings 
are consistent with previous studies that show at least one copy of Mll is required for viability. 5, 
14 However, because the PTD/- mice are not viable, these mice do not allow for the study of how 
the mutation alone affects hematopoiesis or leukemogenesis in adult mice (Figure 2). 
 
Mll conditional knockout 
 In order to address the issue of embryonic lethality associated with PTD/- animals, we 
acquired Mll conditional knockout mice from the lab of Dr. Patricia Ernst.  In these specific 
mice, Mll exons 3-4 are floxed, referred to as Mll-F (Figure 3a). LoxP flanked (floxed) regions of 
genes can be deleted in animals with Cre recombinase using Mx1-driven induction.  This viral 
process activates Cre recombinase to delete the floxed portion after induction with 
polyinosinic:polycytidylic acid (poly I:C).  In these specific mice, Mll exons 3-4 are floxed, 
referred to as Mll-F (Figure 3a).  Before induction, Mll-F mice are phenotypically identical to 
Mll-WT mice.  However, after induction of Mx1-Cre recombinase, Mll exons 3-4 will be 
removed, resulting in deletion of the nuclear targeting sequence and subnuclear localization 
domains of Mll.  Without these domains, Mll is no longer translocated to the nucleus and thus, no 
longer can perform nuclear function as a transcription factor., allowing for an effective knockout 
of the gene, referred to as Mll-∆N15  (Figure 3b).15  Mice lacking Cre recombinase retain 
functional Mll-F in their genotype after induction and serve as controls. 
MllF/F mice and MllWT/F mice are viable and do not have any defects.  Mice induced to 
obtain the MllWT/∆N genotype show a reduction in bone marrow cellularity and hematopoietic 
function, but are capable of surviving with only one normal copy of Mll, as shown by Jude et 
al.15  Adult MllF/F mice that are induced to become Mll∆N/∆N mice die within 3 weeks of Cre 
recombinase induction due to bone marrow failure.  These mice have no functional copies of Mll 
to maintain hematopoiesis, and thus hematopoietic stem cells and progenitors enter the cell cycle 
and are rapidly depleted.15 
 By crossing this conditional Mll deletion model with our Mll-PTD model, MllPTD/F mice 
can be obtained.  After induction of Mx1-Cre, these mice become MllPTD/∆N mice, which allows 
for the study of the Mll-PTD mutation in the absence of any functional Mll-WT, comparable to 
human MLL-PTD+ AML blasts in which MLL-WT transcripts are absent.  By studying 
hematopoietic (and potentially leukemogenic) processes in these mice, the specific role of the 
MLL-PTD mutation can be uncovered.  It is possible that by further uncovering the phenotypes 
and mechanisms associated with this mutation, therapeutic targets will be discovered and these 
findings can eventually be applied to treat MLL-PTD+ AML, despite its poor prognosis. 
Introductory Figures: 
Figure 1 – The Partial Tandem Duplication of Mll 
Mll-PTD maintains all functional domains, yet displays a tandem duplication of AT-hooks and 
the methylbinding domain. 
 










MllPTD/- mice are not viable and die approximately at postpartum day 1.  MllPTD/WT mice are 
viable and do not develop leukemia. 
 
Figure 3 – Cre Recombinase-driven Deletion of Subnuclear Localization Domains to turn 
Mll-F into Mll-ΔN  
 
3a) Mll-F has LoxP flanked sites as denoted by the red lines.  Mll-F is fully functional prior to 
Mx1-Cre induction. 3b) Mll-ΔN is formed from Mll-F mice containing Cre recombinase that are 
induced with poly I:C.  Mll-ΔN is missing the subnuclear localization domain of Mll, and 
therefore is not translocated to the nucleus and serves as a null copy of nuclear Mll WT. 
 
Materials and Methods: 
Formation and observation of MllPTD/∆N Mice 
 In order to generate mice expressing only Mll-PTD without Mll-WT, MllPTD/WT mice were 
crossed with MllF/F mice also expressing Mx1-Cre.  Offspring from these breeders were 
genotyped using tail biopsies in order to test for presence of Mll-PTD, Mll-F, and Mx1-Cre 
recombinase.  At six weeks of age, MllWT/WT, MllPTD/WT, MllF/F, MllWT/F, and MllPTD/F mice were 
given 4 intraperitoneal injections of poly I:C on days 0, 2, 4, and 6.  Poly I:C dosage = (10 x 
animal mass [g] + 50) μg poly I:C. Mice were weighed every day during the induction process, 
and every other day for 60 days following the induction.  After induction, the resulting genotypes 
of the aforementioned mice were MllWT/WT, MllPTD/WT, Mll∆N/∆N, MllWT/∆N, and MllPTD/∆N.  Mice 
lacking Cre recombinase do not experience a change in their genotype.  Mice were then checked 
via PCR for complete deletion of Mll-F, and any mice showing residual expression of Mll-F were 
given an additional dose of poly I:C. 
 
Examination, immunohistochemistry, and cytochemistry 
 Animals were observed daily for overt signs of sickness.  Biweekly blood counts and 
differential assessment beginning at day 0 of induction were taken until animals displayed signs 
of bone marrow failure, as indicated by severe anemia, thrombocytopenia, or leucopenia, or until 
animals displayed extreme lethargy or >20% body weight loss.  At this point, animals were 
sacrificed.  Blood from the animals was used to make smears, followed by Wright-Giemsa 
staining.  In addition, blood was saved in order to perform PCR to confirm deletion.  
Hematopoietic tissues, primarily bone marrow and spleen, were collected.  These samples were 
used to perform immunophenotyping, to extract DNA to further confirm deletion via PCR, 
extract RNA, and prepare cell samples for microscopy and histological analysis.   
 
Quantitative Real-time PCR 
Quantitative RT-PCR was performed using the ABI 7900HT Fast Real-Time PCR System 






 The log-rank test was utilized to compare PTD/∆N survival to the ∆N/∆N control.  A 
one-sample t-test was used to analyze RT-PCR data.  All other results were analyzed using a 
one-way ANOVA test. 
Genotyping and PCR 
 DNA was purified from tail samples as well as from bone marrow, spleen, and blood 
(Extract-N-Amp, Sigma).  Standard PCR protocol was used to amplify the genes.  The primers 
used are as follows: 
Reaction Forward Primer Reverse Primer 
Cre recombinase CCTGTTTTGCACGTTCACCG  ATGCTTCTGTCCGTTTGCCG 
Mll-F CAGTGGACATTCCAACTCTTCAA  GATTGGCCAATGTCTCTCGTAGTAGGC 
Mll-PTD GAGCCTTGGCCCGAATGAAACTGT  CCGGCGAACGTGGCGAGAA 
 
To test for deletion of Mll-F to Mll-∆N, the above primers for Mll-F were used in conjunction 










Figure 4 – Deletion of Mll-F in Induced Animals 
6. Mll-F is shown to be completely converted to Mll-∆N in both bone marrow and spleen. 
 
Figure 5 – The Result of poly I:C Induction 
 
5a. All mice, regardless of genotype, show a marked drop in weight following the poly I:C 
induction.  Following this weight drop, the mice regain and maintain their weight, excluding the 
∆N/∆N mice, which die due to bone marrow failure before their weight is stabilized.  All mice 
with the PTD allele display stunted growth initially.  Error bars represent standard deviation. 
 5b. Kaplan-Meier survival analysis shows that ∆N/∆N mice die on average of 18 days after 
induction, and none survive past day 24 post-induction.  Unlike ∆N/∆N mice, PTD/∆N mice do 
not succumb to bone marrow failure and do not die.  Along with the age-matched control mice, 





Figure 6 – Peripheral Blood Analysis upon Sacrifice 
 
6a.  PTD/∆N mice maintain normal hematocrit levels that are consistent with other controls 
(n=3).  The difference between PTD/∆N hematocrit levels and age-matched control hematocrit 
levels is not statistically significant according to a one-way ANOVA test (p=0.0916).  Error bars 
represent standard deviation. 
7 
6b.  PTD/∆N mice also maintain normal white blood cell counts (n=3).  Mice do not exhibit any 
signs of pre-leukemia as determined by WBC counts.  The difference between PTD/∆N WBC 
counts and age-matched control WBC counts is not statistically significant according to a one-
way ANOVA test (p=0.1693).  Error bars represent standard deviation. 
 
Figure 7 – Histological Analysis of Hematopoietic Tissue 
 
7a. PTD/∆N mice do not have any statistically significant difference in spleen weight when 


























Bone Marrow Histology 
 
7b. ∆N/∆N mice show severe hypocellularity in the bone marrow upon sacrifice, indicative of 
bone marrow failure.  Histological analysis of PTD/∆N bone marrow shows no hypocellularity 









 Figure 8 – Elevated transcript levels of downstream target of Mll in PTD mice 
 
Mice with the PTD allele display elevated mRNA transcript levels of HoxA9 (p=0.0225) relative 
to age-matched F/F controls (n=3 for all samples except for PTD/F for which n=1). Error bars 
represent standard deviation. 
 
Discussion 
 Based on the finding by Whitman et al. that MLL-WT is silenced in MLL-PTD+ AML 
blasts12, this study sought to determine how the PTD mutation mediates hematopoiesis, if at all, 
in the absence of WT expression.  Utilizing a novel mouse model, PTD was able to be expressed 
without the WT gene in PTD/∆N mice, allowing for this study to circumvent the embryonic 
lethality of the expression of solely the Mll-PTD mutation.  Leukemogenic MLL fusion 
mutations have been shown to require the presence of MLL-WT.  Therefore, it was initially 
hypothesized that the Mll-PTD acts in a similar fashion and would not be able to carry out 
normal hematopoiesis without Mll-WT. Ultimately, the long-term goal of this study is to take 
steps to positively impact MLL-PTD+ AML patients by uncovering mechanisms and therapeutic 
targets through an enhanced understanding of the basic biology of the disease.   
 Upon weighing both before and after poly I:C induction, it was noted that mice with the 
PTD allele weigh less than those without the PTD mutation.  This is most likely attributed to 
defects in Hox gene expression11,13, and this phenotypic difference did not affect the induction 
process or trends in weights of these mice.  Upon induction, all mice displayed a drop in weight, 
characteristic of the immune system stimulation associated with the poly I:C19.  The weights of 
the PTD/∆N mice stabilized along the same time as the other age-matched controls (F/F, WT/F, 
and PTD/F).  However ∆N/∆N mice do not regain weight, and died 3 weeks after induction from 
bone marrow failure, a finding indicative of the absence of the Mll-F due to its conversion to 
Mll-∆N (Figure 5a).  Consistent with Dr. Ernst’s previous findings, ∆N/∆N mice succumb to 
bone marrow failure on average of 18 days as a result of the lack of any functional Mll to salvage 
hematopoesis.  In contrast with the initial hypothesis, PTD/∆N mice showed very different 
survival than the ∆N/∆N mice (p<0.001).  Indeed, no difference in survival time has been 
observed after over one year between the PTD/∆N mice and the remaining age-matched controls, 
implying that the absence of Mll-WT does not lead to AML in PTD/∆N mice.  Toxicity of the 
poly I:C induction did not result in death of any PTD/∆N mice (Figure 5b).   
The ongoing survival of the PTD/∆N mice could be attributed to three possible 
explanations.  The first possibility was that the poly I:C induction was not complete and there 
were still some Mll-F alleles that were functioning in these mice and had not been converted to 
Mll-∆N.  Utilizing forward, reverse, and deleted reverse primers as previously indicated, PCR 
analysis of spleen, bone marrow, and blood displayed complete deletion of Mll-F, eliminating 
incomplete deletion as a feasible explanation (Figure 4).  Another possibility is that the Mll-WT 
is being shuttled into the nucleus by Mll-PTD via dimerization domains that may be retained.  
Although unlikely, this hypothesis is currently being tested by Dr. G. Huang at Cincinnati 
Children’s. The third possibility was that our initial hypothesis was not correct, and Mll-PTD 
was indeed capable of effectively functioning and salvaging hematopoiesis in these mice.  Blood 
counts of PTD/∆N mice showed that hematocrit levels (Figure 6a) and white blood cell counts 
(Figure 6b) in these experimental mice are maintained at levels similar to those of the normal 
control mice.  Leukemic and pre-leukemic mice often display enlarged spleen size, however 
PTD/∆N mice, like the PTD/WT mice, (Figure 7a) did not have enlarged spleens.  Furthermore, 
histological analysis of bone marrow displayed considerable hypocellularity in the ∆N/∆N mice, 
indicative of depletion of hematopoietic stem/progenitors, resulting in bone marrow failure.  
However, along with the age-matched control mice, PTD/∆N mice displayed no hypocellularity 
and no signs of pre-leukemia in the bone marrow (Figure 7b).  All of these results lead to the 
conclusion that the Mll-PTD protein is in fact capable of salvaging hematopoesis in adult mice 
lacking Mll-WT expression. 
 Analysis of all major adult hematopoietic tissues indicate that PTD/∆N mice are capable 
of maintaining hematopoiesis at levels relative to the wild-type controls.  Thus, it follows that the 
PTD mutation, contrary to leukemogenic MLL fusions, is capable of salvaging hematopoiesis at 
normal levels in the absence of Mll-WT.  Going on 500 days after induction, PTD/∆N mice show 
no signs of leukemia and continue to live and reproduce normally.  Although no pre-leukemia 
phenotypic signs are found in these mice, preliminary data showed that transcript levels of 
Hoxa9, a major downstream target of Mll, were elevated in both PTD/F and PTD/∆N mice 
(Figure 8), suggesting that Mll-PTD is acting in a gain-of-function manner, confirming the 
findings of Dorrance et al11 and Whitman et al12 in this experiment’s adult mice lacking Mll-WT 
expression.  The elevated mRNA transcript levels do not lead to leukemogenesis or altered 
hematopoiesis, but multiple possibilities exist to explain the implications of Mll-PTD acting in a 
gain-of-function manner.  Firstly, transcript levels are not always indicative of translated protein 
levels, and it is possible that the elevated HoxA9 transcript levels shown in PTD mice do not 
translate to elevated HoxA9 protein expression.  It follows that one such future experiment to be 
conducted is to utilize western blotting to observe HoxA9 protein levels in the PTD/∆N mice.  
Alternatively, the elevated transcript levels could simply be the first “hit” to leukemogenesis, and 
the accumulation of other mutations would combine either additively or synergistically to lead to 
leukemia.  Recently our lab published on a double knock-in model of Mll-PTD together with the 
Flt3-ITD, the internal tandem duplication mutation of Fms-like tyrosine kinase 3.  It was shown 
that AML did not develop in the knock-in mice with only the PTD or only ITD mutation, 
although some models have shown that certain retrovirally-expressed Flt3-ITD mutations can be 
leukemogenic.20 Leukemia does develop in mice with both the PTD and the ITD, supporting the 
hypothesis that the gain-of-function of Mll PTD is necessary but insufficient to cause AML and 
thus requires a second mutation, like Flt3-ITD.20   
 This project has uncovered a gain-of-function role for the Mll-PTD mutation in adult 
hematopoiesis.  Armed with the basic biology of the functioning of Mll-PTD, we hope to 
eventually develop targeted therapies for patients with MLL-PTD+ AML.  In order to reach that 
point, we must still further uncover the mechanisms by which the MLL-PTD mutation causes 
leukemogenesis.  One future experiment to further investigate into the role of MLL-PTD is to 
perform serial competitive repopulation studies in order to determine the self-renewal capacity of 
PTD/∆N hematopoietic stem cells and progenitor cells relative to controls.  Given the gain-of-
function action of Mll-PTD, I hypothesize that these studies will show an increased self-renewal 
capacity and repopulation capability of cells with the PTD mutation, a finding that would further 
implicate the gene as a contributing factor in leukemogenesis.  In addition to this, continued 
monitoring of the PTD/∆N mice is important.  As aforementioned, age and chromosomal 
condition are the two key factors in leukemogenesis and prognosis of AML.  Although our mice 
are currently entering into old age, it is still possible that age could affect progression of the 
disease, if any arises. 
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